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ABSTRACT 
Squamous cell carcinoma (SCC) is the second most common type of skin cancer 
in the United States with around 3.5 million cases diagnosed every year. Protein Kinase C 
(PKC) is a family of 9 serine/threonine kinases having distinct role in cell proliferation, 
differentiation, apoptosis and angiogenesis. One widely expressed isoform of PKCs, 
PKC-δ has been shown to act as a tumor suppressor in skin cancer by mediating cell 
apoptosis. Re-expression of PKC-δ in human SCC cells induced apoptosis and 
suppressed tumorigenicity in vitro. PKC-δ expression is lost in 30% of human SCC 
tumors and is repressed in keratinocyte cell lines expressing activated HRAS.  The 
Denning lab showed earlier that this loss of PKC-δ is at the transcriptional level and 
involves the Ras pathway shown below.  
We hypothesize that compounds inhibiting this pathway will re-induce PKC-δ 
gene expression and will be effective therapeutic agents in SCC. In order to test the 
hypothesis, we proposed development of a high throughput, cell-based reporter assay on
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Ras transformed keratinocyte cell line, HaCaT-Ras to measure PKC-δ promoter activity 
and screen compounds having potential to induce PKC-δ promoter activity. 
In this study, we utilized a PKC-δ promoter reporter plasmid (pGL3-hPKCδ-4.4) 
generated earlier in our lab to assess PKC-δ promoter activity, in which 4.4 kb region of 
human PKC-δ promoter was inserted next to luciferase reporter gene. The first goal of 
this project was to develop a HaCaT-Ras cell line stably transfected with PKC-δ reporter 
plasmid. To do this, we co-transfected HaCaT-Ras cells with PKC-δ reporter and EGFP 
plasmids, and sorted EGFP positive cells by flow cytometry to select clones which were 
stably transfected with EGFP. In the next step, clone screening, we identified one clone 
having stable PKC-δ reporter expression. Thus we were successful in generating a stable, 
PKC-δ promoter-reporter transfected HaCaT-Ras cell line. 
The second aim of this study was to identify positive control compound(s) that 
give high induction in PKC-δ promoter activity to characterize and validate this assay. To 
pursue this aim, we tested 13 compounds belonging to different pharmacological classes 
either alone or in the combination for their ability to induce PKC-δ promoter activity on 
HaCaT-Ras cells transiently transfected with PKC-δ reporter. We identified src-family 
kinase inhibitor PP2 and the combination of NF-κB inhibitor Bay11-7085 and PKC 
activator TPA as reasonable positive control compounds for this assay. We proposed to 
perform this assay on microplate reader PHERAstar FS, and optimized the protocol on 
this instrument so that resulting high-throughput screening assay has higher Z value 
(statistical parameter directly related with quality of high-throughput screening) and 
convenience. After series of experiments which tested effects of various time-points of 
luminescence measurements, optic settings, and durations of shaking on quality of assay, 
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we were able to generate a protocol which offered less variability and accurate signal 
measurement on PHERAstar FS.  
To conclude, in this project we generated a HaCaT-Ras cell line stably transfected with 
PKC-δ promoter-reporter plasmid (pGL3-hPKCδ-4.4), and a protocol for high throughput 
luciferase reporter assay in PHERAstar FS. Overall, these studies will be very helpful in 
future for developing a robust, high-throughput screening assay to screen large number of 
compounds which have potential to induce PKC-δ gene expression.
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CHAPTER 1 
BACKGROUND 
Squamous Cell Carcinoma 
Skin cancer is the most frequent form of cancer in the United States with around 3.5 
million new cases diagnosed every year (1). There are two major types of skin cancers 
depending on their cells of origin in the skin tissue. In melanoma skin cancer, cancer 
originates in melanocytes, cells responsible for producing the pigment melanin. The other 
type of skin cancer is non-melanoma skin cancer, where cancer originates from 
keratinocytes in the skin. Non-melanoma skin cancer is again divided into two sub-
classes namely basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). 
Squamous cell carcinoma (SCC) is the second most common (around 20% of non-
melanoma skin cancers) type of skin cancer in the US (2, 3). As SCCs may be fatal if not 
treated properly, a safe and efficacious therapeutic strategy is required to make treatment 
better, and reduce its mortality rate. Currently primary treatment option for SCC includes 
surgery. However, it has adverse effects such as skin scarring, irritation, redness, loss of 
pigments, and is economically expensive. To avoid these clinical side-effects and make 
treatment more economically affordable to patients, a second treatment approach, 
chemotherapy may be used to treat SCC. However, applicability of this approach is 
limited by the fact that only a handful of topical agents such as 5-fluorouracil, and 
imiquimod are available to treat SCC today. Hence, more effective pharmacological 
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agents that alleviate and eliminate SCC are of crucial need to provide better treatment 
options to SCC patients.  
 PKC-δ as a tumor suppressor in SCC 
Protein Kinase C (PKC) is a family of 9 serine/threonine kinases having distinct role in 
cell proliferation, differentiation, apoptosis and angiogenesis (4, 5). PKCs reside in the 
cell cytosol in their inactive state. Activation of most PKCs takes place by their 
recruitment into the cell membrane and allosteric activation by diacylglycerol (DAG) (4, 
5). Calcium enhances the process of activation of classical PKCs-α, β, and γ (4, 5). When 
upstream mediator of the signal is a tyrosine kinase receptor, production of DAG in the 
cell membrane results from cleavage of phosphotidylinositol 4,5-bisphosphate (PtdIns 
(4,5)P2) by phospholipase C-γ (PLC-γ) (4, 5). In contrast when the signaling is conducted 
by G protein-coupled receptors (GPCRs), Gαq subunit interacts with PLC-β which results 
in cleavage of PtdIns (4,5)P2 and synthesis of DAG in the cell membrane (4, 5). Once 
activated, PKCs are phosphorylated on their kinase domains and phosphorylate their 
downstream substrates which can result in any of the different biological effects of PKCs 
including regulation of cell growth and differentiation.  
One widely expressed isoform of PKCs, PKC-δ, induces growth arrest in several types of 
cells upon its activation (6, 7) and is shown to be pro-apoptotic in renal, neuronal and 
breast cell lines (8, 9, 10). Our lab has previously shown that PKC-δ is both necessary 
and sufficient for apoptotic cell death in human keratinocytes after exposure to UV light 
(11, 12, 13). PKC-δ is activated by caspase-3 mediated cleavage in response to apoptotic 
stimulus resulting in its constitutionally active catalytic fragment in human keratinocytes 
(11). This constitutionally active PKC-δ fragment in turn phosphorylates and 
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downregulates anti-apoptotic Mcl-1 protein in mitochondria, resulting in cytochrome C 
release and apoptosis (14). Over-expression of PKC-δ in keratinocytes by retroviral 
infection reduced their growth by inducing apoptosis in vitro (15).  
A tumor suppressor gene is defined as a gene which prevents or inhibits formation of 
tumors, and its expression is often lost in the cancerous tissue. The Denning lab explored 
PKC-δ’s role as a tumor suppressor in squamous cell carcinoma and found that 30% of 
human SCC-tissue samples showed loss or reduction of PKC-δ protein (15). Also, 
transgenic mice over-expressing PKC-δ are resistant to chemically induced SCCs (16). 
Interestingly, re-expression of PKC-δ in HRAS transformed human keratinocytes grafted 
in nude mice dramatically inhibited tumor growth in vivo (15). Taken together, it is clear 
that PKC-δ plays prominent role in eliminating pre-cancerous cells by mediating UV 
induced apoptosis in human keratinocytes, and has tumor suppressor properties in SCC. 
Thus increasing expression or activity in SCC might be a promising strategy to develop 
novel therapeutics for SCC. 
Correlation between PKC-δ loss and Ha-Ras 
Ras is a family of small GTPase proteins found in human cells encoded by three genes 
named as HRAS, KRAS and NRAS. These GTPase proteins are activated through 
various external stimuli (e.g. mitogens such as EGF) and subsequently activate 
downstream effectors that control cell growth, differentiation and survival. Gene 
amplification or activating mutation in Ras gene leads to aberrant cell growth or 
differentiation, often leading to cancer (17, 18).  
As in other human cancers, activating Ras mutations are found in SCCs, where around 
50% of SCCs carry activating Ras mutations (19). As significant proportion of human 
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SCCs have active Ras mutations (19) as well as loss of PKC-δ (15), it is possible that 
these both events are correlated with each other in human SCCs. In Over 90% of 
chemically induced mouse tumors have been shown to carry activating Ha-Ras (a 
member of Ras family of proteins, encoded by HRAS gene) mutations (20). In the 
HaCaT immortalized human keratinocytes cell line, expression of activated Ha-Ras 
reduces PKC-δ protein and mRNA levels (21). It has also been demonstrated earlier that 
in vitro transduction of active Ras in keratinocytes isolated from mice, highly induces 
mRNA expression of several EGFR ligands such as TGF-α, heparin binding EGF like 
factor, betacellulin (22). This phenomenon results in generation of autocrine loop by 
active Ras, where high levels of EGFR ligands lead to over-activation of EGFR in Ras 
transformed keratinocytes. Furthermore, majority of human SCC-tissue samples which 
showed reduced PKC-δ levels also stained positive for phospho-EGFR (15) suggesting 
activation of Ras in these tumors (15). Phospho-EGFR was not detected in normal human 
skin (15). Thus we propose that it is activating Ha-Ras mutation that confers reduction in 
PKC-δ protein expression.  
PKC-δ loss on transcriptional level 
The Denning lab published in 2010 that loss of PKC-δ expression in human SCC is on 
transcriptional level (23). They selected 14 human SCC-tissue samples which showed 
loss of PKC-δ expression in immunohistochemistry, and all of these samples expressed 
low PKC-δ mRNA levels, when measured by qRT-PCR (23). Also in gene-deletion 
analysis using qPCR, 8 out of 9 SCC tumors had intact PKC-δ gene, supporting 
transcriptional repression as a major process contributing to PKC-δ loss in SCC (23). 
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After establishing a relationship between activating Ras mutations and PKC-δ loss 
earlier, our lab extended studies on Ras transformed HaCaT cells in vitro. Ras 
transformed HaCaT cells, named as HaCaT-Ras had lower endogenous PKC-δ mRNA 
levels compared to HaCaT cells (23). To assess PKC-δ promoter activity, the promoter 
region of human PKC-δ gene from a BAC clone (RPCI-11-82B23, BACPAC Resources, 
Children’s Hospital Oakland Research Institute) was sub-cloned into the firefly luciferase 
reporter construct pGL3-Basic vector (Promega) to generate pGL3-hPKCδ-4.4 plasmid 
(23). As shown in the Figure 1, a 7.4 kb region of PKC-δ gene was excised from BAC 
clone using XhoI and EcoRV enzymes in first step. Then, 4.4 kb region of PKC-δ 
promoter was excised using XhoI and SacII enzymes and sub-cloned into XhoI and 
HindIII restriction sites of pGL3-basic vector. Resulting pGL3-hPKCδ-4.4 construct was 
then used to measure PKC-δ promoter activity in different cell lines. When this construct 
was transfected into HaCaT-Ras cells, they showed significantly less PKC-δ promoter 
activity compared to HaCaT cells (23). This result confirmed that Ras mediated PKC-δ 
transcriptional loss in keratinocytes is due to reduction in PKC-δ promoter activity.
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Figure 2 illustrates restriction-site map of pGL3-hPKCδ-4.4. 
 
  
  
Figure 1: pGL3-hPKCδ4.4 Construction: 7.4 kb fragment of PKC-δ gene of 
was excised from 180 kb-BAC clone, followed by sub cloning 4.4 kb region of 
PKC-δ promoter into pGL3 basic vector. 
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PKC-δ gene regulation studies 
Although functions of PKC-δ have been studied widely, few studies have been done to 
understand its gene regulation. The 31 kb long human PKC-δ gene is located at 3p21.31 
region of the human chromosome (24). It comprises of 18 exons. In 2003, Suh et al. 
studied a 1.7 kb promoter region of murine PKC-δ gene, and showed that NF-κB 
increases PKC-δ promoter activity, resulting in increase in its expression (24). When 
mouse keratinocytes were transfected with murine PKC-δ promoter and treated with 
TNF-α, an activator of NF-κB, they showed higher reporter activity compared to 
untreated keratinocytes (24). This increase in reporter activity by TNF-α was abrogated 
by infecting keratinocytes with superrepressor IκB, a negative regulator of NF-κB (24). 
Liu and co-workers in 2006 showed that RelA, a major transactivating subunit of NF-κB 
positively regulates PKC-δ expression in mouse fibroblasts (25). This positive regulation 
was a result of increase in PKC-δ promoter activity mediated by interaction of RelA with 
Figure 2: pGL3-hPKCδ4.4 Plasmid Map: 4.4 kb promoter region of PKC-δ 
gene was sub-cloned into pGL3 basic vector between restriction sites XhoI and 
HindIII (17). Total length of pGL3-hPKCδ4.4 was 9.2 kb. Diagram of pGL3-
Basic Vector is a copyright of Promega Corporation. 
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two NF-κB binding sites identified in the same studies at -83 to -74 and -52 to -43 sites in 
-309 to -1 region of human PKC-δ promoter (25). Other studies done on PKC-δ gene 
regulation in past demonstrated that molecules p63, p73 in keratinocytes and SP1 in 
skeletal muscle cells also play role in positively regulating PKC-δ promoter activity (26, 
27).  
A former Ph.D. student of the Denning lab, Vipin Yadav attempted to dissect the 
signaling pathway downstream of activated Ha-Ras that leads to transcriptional 
repression of PKC-δ promoter activity. In his study, TFSearch analysis identified many 
potential transcription factor binding sites such as NF-κB, c-Ets, AP-1 in 4.4kb long 
human PKC-δ promoter (Figure 3). Site directed mutagenesis of NF-κB binding motif at 
-311 site in PKC-δ promoter resulted in 20 fold increase in PKC-δ promoter activity in 
HaCaT-Ras cells. Further, ChIP analysis using PCR primers that corresponded to NF-κB 
binding sites at -311 and -301 on PKC-δ promoter revealed that p50 and c-Rel subunits of 
NF-κB are specifically recruited to PKC-δ promoter in HaCaT-Ras cells. These results 
suggested that NF-κB plays prominent role in Ras mediated repression of the PKC-δ 
promoter. The data he generated further suggests that activated Ras activates PI3K, which 
activates Fyn (Src-family kinase), which subsequently phosphorylates IκB-α, a negative 
regulator of NF-κB (Yadav, Denning, Personal communication, Figure 4). This leads to 
degradation of IκB-α and activation of NF-κB, which finally represses PKC-δ promoter 
activity (Yadav, Denning, Personal communication, Figure 4). This proposed mechanism 
of active Ha-Ras leading to low PKC-δ promoter activity (Yadav, Denning, Personal 
communication, Figure 4) might be useful in devising therapeutic strategies to increase 
PKC-δ promoter activity in human keratinocyte cell line.  
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Figure 3: Potential Transcription Factor Binding Sites on the Human PKC-δ 
Promoter: In schematic depicting potential transcription factor binding sites on 
4.4 kb PKC-δ promoter region, please note the functional NF-κB binding site -
311 (second arrow pointing upward from the right side) on promoter. 
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High Throughput Screening 
High throughput screening (HTS) is a process of drug-discovery in which large numbers 
of molecules belonging to the pharmacological classes of interest are tested for their 
ability to produce measurable biological or chemical change in the system in highly 
accurate, sensitive, convenient, automated, as well as time and cost-efficient manner. 
Chemical compound libraries might contain 100,000 to as many as 1 million molecules, 
Figure 4: Proposed pathway leading to PKC-δ transcriptional repression 
after Ras activation: Activated Ras activates PI3K, which further activates src-
family kinase Fyn. Activated Fyn in turn phosphorylates and degrades IκB-α 
which activates NF-κB comprising p50 and c-Rel subunits. NF-κB finally 
translocates into nucleus and repressed PKC-δ promoter. 
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high throughput screening of which is conducted mainly in 96, 384 or 1536 well plate to 
allow miniaturization and automation. It also often involves robotics and automatic liquid 
handling systems. In screening, compounds which have desired biological or chemical 
effect of quantum above the set threshold are called ‘hits’. These hits are subjected to 
additional biochemical, pharmacological and clinical tests in next steps to find out the 
best compound having potential to become a therapeutic agent. 
HTS majorly involves two types of assays, namely biochemical and cell-based assays 
(28). Bio-chemical assays include isolation of biological or chemical target, and direct 
measurement of effect of drug candidates on target in vitro in environment suitable for 
biochemical measurements (29-35). Cell-based assays, which are performed on cells 
grown in vitro (36-41), are increasingly preferred over biochemical assays for HTS due to 
their similarity to physiological environment and larger scope of studies extending 
beyond just one target to multiple targets and whole signaling pathways (28). In addition 
to these two conventional approaches, many whole organism-based screening assays 
have been developed (42-52) in attempt to make HTS as physiologically relevant as 
possible. 
Cell-based assays represent at least half of all the HTS assays performed today (53). 
Major subtypes of cell-based assays are second messenger, reporter gene and cell 
proliferation or toxicity assays (53). Cell-based reporter gene assays are widely used to 
measure transcriptional or promoter activity of gene of interest. There have been many 
studies where cell-based reporter assays are successfully developed in high throughput 
format (38, 39, 54-57). Recently a group of researchers in Switzerland developed a 
HaCaT keratinocyte-based, high throughput luciferase reporter assay to test compounds 
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for their ability to sensitize the skin by inducing promoter of human AKR1C2 gene (58). 
In this study, HaCaT cell line stably transfected with pGL3 basic vector carrying 
antioxidant response elements (AREs) of human AKR1C2 gene was created using drug 
selection approach (58). This cell line was then used to screen numerous compounds and 
assess the statistical parameters of the assay (58). 
Validation of HTS 
After HTS assay has been designed, it is validated using statistical parameters. Zhang et 
al has very well defined a parameter to assess usefulness of assay for high throughput 
screening known as Z-factor (59). Z-factor is defined as follows (59):  
 
    1 - 
3 Standard Deviation of Positive Control  3 Standard Deviation of Negative Con rol
  Mean of Positive Control - Mean of Negative Control  
  
Following are the interpretations of Z values for HTS (59): 
Table 1: Inferences of Z values in High-Throughput Screening (59) 
Z value Inference for screening 
1 An ideal assay. 
0.5≤ <1 An excellent assay 
0<Z<0.5 A doable assay 
0 A yes/no type assay 
<0 Screening essentially impossible 
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Objective and hypothesis 
Our objective was to develop a stable cell-based reporter assay that could accurately 
detect relative PKC-δ promoter activity so that high throughput screening of compound 
libraries could be performed to identify compounds that induce PKC-δ transcription. The 
identified compounds (also referred to as ‘hits’) could be suitable candidates for novel 
drug development project for SCC, as even small increase in apoptosis can cause 
relatively large growth inhibition in regressing skin tumors (60). We proposed following 
hypothesis for this project. 
Compounds belonging to specific classes such as NF-κB inhibitors, or src-family kinase 
inhibitors, induce PKC-δ gene expression in stably transfected, PKC-δ reporter-human 
keratinocytes cell line which is Ras-transformed. 
We identify following specific aims to test this hypothesis. 
Specific Aims 
Aim 1: To develop a stably transfected PKC-δ promoter-reporter cell line, suitable 
for high throughput screening.  
Aim of developing a stable PKC-δ reporter cell line, suitable for high throughput 
screening forms the backbone of this project, as this cell line could be used in developing 
assay as well screening of compounds. 
This aim has been divided into following sub-aims for convenience. 
Sub-Aim 1A: Transfection and sub-sequent selection/sorting of transfected cells 
followed by selection of clones. 
Sub-Aim 1B: Screening of selected clones. 
14 
 
 
 
Aim 2: To identify positive control compounds which induce PKC-δ promoter 
activity and validation of PKC-δ reporter assay. 
This aim has been divided into following sub-aims for convenience. 
Sub-Aim 2A: To identify positive control compounds which induce PKC-δ promoter 
activity. 
It is very important for this project to identify in prior some compounds which induce 
PKC-δ gene expression to use them as positive controls for screening libraries of 
compounds. 
Sub-Aim 2B: Validation of PKC-δ reporter assay. 
Validation of assay i.e. all experimental conditions such as clone, positive control, plating 
density is highly important step before going to screening stage. It allows researcher to 
assess whether the assay is applicable to high throughput screening or needs further 
optimization. 
Sub-Aim 2C: Investigating Ras and PKC-δ expression in HaCaT-Ras and other cell 
lines.
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CHAPTER 2 
MATERIALS AND METHODS 
Cell Culture 
Both the HaCaT and HaCaT-Ras cells were cultured in Dulbecco’s Modified Eagle 
Medium (DMEM, Life Technologies, Carlsbad, CA) supplemented with 10% Fetal 
Bovine Serum (FBS) and 1% Penicillin Streptomycin (Pen Strep). MDA-MB-231 cells 
were cultured in Improved Minimum Essential Medium (IMEM, VWR, Radnor, PA) 
supplemented with 5% FBS, 1% L-glutamine, and 1% non essential amino acids. To 
enhance growth of single HaCaT and HaCaT-Ras cells plated in 96 well plates after flow-
cytometric cell sorting, either medium was supplemented with 10 ng/mL of human EGF, 
or regular medium and conditioned medium (medium collected from plate of similar cells 
when cells reached around 80% confluency) were used in 1:1 proportion.  
Drugs and compounds 
Compounds used in this project were PP2 (Life Technologies, Carlsbad, CA), Dasatinib 
(LC Laboratories, Woburn, MA), LY294002 (Alexis Biochemicals, San Diego, CA), Bay 
11-7085 (Santa Cruz Biotechnology, Dallas, TX), Bortezomib (Millennium 
Pharmaceuticals, Cambridge, MA), MG132, GDC-0941 (Chemietek, Indianapolis, IN), 
Wortmannin (Alexis Biochemicals, San Diego, CA), Vitamin D3 (Sigma, St Louis, MO), 
TNF-α, estrogen (Sigma, St Louis, MO), insulin and TPA (Alexis Biochemicals, San 
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Diego, CA). Stock solutions were made in either DMSO or DEPC-treated water 
depending on vehicle recommended by manufacturer for different compounds. 
DNA Plasmid 
pGL3-hPKCδ-4.4 has been described previously (Figure 2, Reference 23). Renilla 
luciferase control pRL-CMV was purchased from Promega, Fitchburg, WI. EGFP 
plasmid pEGFP-C1 (Clontech, Mountain View, CA) was a gift from Dr. Clodia Osipo. 
Transfection 
Transfections were performed using TransIT 2020 (Mirus, Madison, WI) or FuGENE 6 
(Roche, Indianapolis, IN) by following manufacturer’s protocol. Briefly, on the day of 
transfection media on the cells was removed and replaced with regular DMEM for 
TransIT 2020 or serum-free Opti-MEM (Life Technologies, Carlsbad, CA) for FuGENE 
6. Recommended quantities of plasmid DNA and transfection reagent were mixed and 
incubated at room temperature for 30 minutes to allow complex formation, followed by 
addition of appropriate volume of this mixture into each well. Amounts of plasmid DNA 
transfected for different experiments are reported in their individual sections. MDA-MB-
231 cells were transfected using Lipofectamine (Life Technologies, Carlsbad, CA) 
according to manufacturer’s protocol.  
Dual Luciferase Assay 
HaCaT or HaCaT-Ras cells were plated on 12 well plate at density of 150,000 cells or 
200,000 cells per well respectively. 24 hours after plating, firefly luciferase reporter 
plasmid (pGL3-hPKCδ-4.4) and renilla luciferase control plasmid (pRL-CMV) were 
transfected into cells using TransIT 2020 or FuGENE 6 by methods described in 
Transfection section. In each well of a 12 well plate, 0.5 µg of firefly and 0.05 µg of 
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renilla luciferase plasmids were transfected. In experiments where cells were treated with 
drugs, drug treatments were started 24 hours after transfection. 48 hours after starting 
drug treatment, cells were lysed and firefly and renilla luciferase activities were measured 
using Dual Luciferase Reporter Assay (Promega, Fitchburg, WI) as per manufacturer’s 
instructions in Zylux bench-top luminometer. In experiments where cells were not treated 
with drugs, 48 hours after transfection luciferase activities were measured.  
Flow Cytometry 
Cells were washed with PBS- once and trypsinized. After trypsinization cells were 
suspended either in PBS with 1% BSA in PBS or DMEM with 10% FBS, followed by 
sorting of highly EGFP positive cells in BD FACSAria III (Becton Dickinson, Franklin 
Lakes, NJ). Each sorting was performed on single cells gated from a mixed population. 
Wherever necessary, sorted cells were directly plated in 96 well plate as single cell per 
well.  
Single Luciferase Assay 
Cells were plated on p60 or 6 well-plate in a way that they were around 60% confluent 
the next day. 24 hours after plating, pGL3-hPKCδ-4.4 was transfected into cells using 
FuGENE 6. Roche recommended ratio of 3 μL of FuGENE 6 for 1 μg of pGL3-hPKCδ-
4.4 was used for transfection. One day after transfection, HaCaT or HaCaT-Ras cells 
were plated in 96 well plate at a density of 20,000 or 50,000 cells per well respectively. 
Volume of DMEM in which cells were plated was 95 µL per well. The next day, drug 
treatments were initiated on cells by adding 5 µL of drug stock solutions per well, where 
concentrations of stock solutions were 20 times higher than the required concentrations. 
48 hours after starting drug treatments, luminescence was measured in PHERAstar FS 
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microplate reader (BMG Labtech, Cary, NC) using Steady-Glo Luciferase Assay System 
(Promega, Fitchburg, WI) following Promega’s protocol. For experiments where cells 
were not treated with drugs, luminescence was measured 48 hours after plating cells. 
Time point of luminescence measurement after addition of Steady-Glo luciferase assay 
reagent varied with different experiments. 
Luminescence and Fluorescence Measurements in PHERAstar FS 
All measurements were performed on PHERAstar FS with the help of BMG Labtech’s 
software and operating manual. For luminescence measurements, automatic injection 
function of PHERAstar FS was used to add luciferase assay reagent into 96 well plates. 
Speed of injection was chosen as 100 µL/second. 10 minutes after adding reagent, 
luminescence was measured in a ‘Plate Mode’ using ‘Bottom Optics’. Plate was read 
after enabling 6 mm of ‘Orbital Averaging’, a function which averages out multiple read-
outs taken across a specific diameter instead of taking just one read-out from a single 
point. Delay was 0.52 seconds. Focal height adjustment was performed on whole plate 
every time before reading luminescence. In experiments where plates were shaken after 
injecting the reagent, more than one kinetic cycle were chosen depending on 
experimental conditions such as shaking time, number of measurements, otherwise plates 
were read using one kinetic cycle. Shaking was performed by choosing ‘Additional 
Shaking’ option in injection settings, where required speed and mode of shaking was 
chosen.  
Fluorescence intensities were measured in ‘End Point Mode’, using appropriate 
excitation and emission module in PHERAstar FS. Before each measurement focal height 
and gain were adjusted for whole plate. 
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Cell Viability Assays 
For Alamar Blue assay (Life Technologies, Carlsbad, CA), 10 µL of Alamar Blue reagent 
was added to 100 µL of media in each well of 96 well plates. Then the plates were 
incubated at 37˚ C for approximately 2 hours. After incubation, fluorescence on plates 
was read using excitation/emission filter of 544/590 nm on POLARstar Omega (BMG 
Labtech, Cary, NC) as per manufacturer’s instructions. To perform Cell Titer-Fluor Cell 
Viability Assay (Promega, Fitchburg, WI), manufacturer’s protocol was followed. 
qRT-PCR 
For qRT-PCR, total RNA was isolated from cells using TRIzol Reagent (Life 
Technologies, Carlsbad, CA) following manufacturer’s protocol. Isolated RNA was 
converted to cDNA, and qRT-PCR was performed using SYBR Green real-time PCR kit 
(Life Technologies, Carlsbad, CA). GAPDH was a normalizing control for all the qRT-
PCRs. The sequences of primers were 5’-CAGATTGTGCTAATGCGGGC-3’ 
(Forward), 5’-TTTGCAATCCACGTCCTCCA-3’ (Reverse) for PKC-δ, 5’-
AGTCGCGCCTGTGAACG-3’ (Forward), 5’-CGTCATCGCTCCTCAGGG-3’ 
(Reverse) for Ha-Ras, 5’-GGCAGCCCTGTACGGGAGGT-3’ (Forward), 5’-
GCTCCACCTGCTCCAGCACC-3’ (Reverse) for Fyn, and 5’-
ACACTCAGCATCATCAAACTCAA-3’ (Forward), 5’-
TTCAGTGATAGCATCACCATGTC-3’ (Reverse) for GAPDH. 
Statistical Analysis 
Student’s T test was performed to calculate the P values and determine the statistical 
significance of the data. The difference observed between two experimental groups was 
considered statistically significant if the P value was less than 0.05.
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CHAPTER 3 
RESULTS 
pGL3-hPKCδ-4.4 isolation and verification 
To transfect PKC-δ promoter-reporter plasmid into cells, we isolated pGL3-hPKCδ-4.4, 
which is firefly luciferase reporter plasmid of 4.4 kb human PKC-δ promoter, from 
bacteria using QIAGEN Plasmid Midi kit according to manufacturer’s protocol. The 
length of isolated plasmid was verified by linearizing it with restriction enzyme XhoI, 
and running it on 0.8% agarose gel. In Figure 5, length of a linearized plasmid is 
approximately 9 kb (lane 3), which closely resembles length of pGL3-hPKCδ-4.4 (9.2 kb, 
Figure 2).
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Figure 5: Identification of 9.2 kb long- pGL3-PKC-δ-4.4 plasmid: 1 µg of 
pGL3-PKC-δ-4.4 plasmid was run on 0.8% agarose gel either uncut or linearized 
after digesting with XhoI. 
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Sensitivity of HaCaT-Ras cells to different drugs 
In order to develop a stably transfected HaCaT and HaCaT-Ras cell lines using drug-
selection approach, we sought to determine drugs to which both the cell lines were 
sensitive, and the optimal concentrations of drugs at which all the sensitive cells on the 
plates were killed. To determine this, we treated HaCaT and HaCaT-Ras cells with 
different concentrations of different drugs over different time durations. Results of these 
experiments are summarized in following table.  
Table 2: Sensitivity of HaCaT and HaCaT-Ras cells to various drugs 
HaCaT and HaCaT-Ras cells were treated with following drugs with specified 
concentration range and time duration. Results are stated in ‘Sensitivity’ column. 
(O.C = Optimal Concentration at which all the cells died, o.m.p = over multiple passages, 
Note: Sensitivity of HaCaT cells to blasticidin and puromycin was not tested as they were 
already sensitive to G418 and Hygromycin.)  
 HaCaT HaCaT-Ras 
Drug 
Concentration 
Range Tested 
(µg/mL) 
Time 
Duration of 
Drug 
Exposure 
(Days) 
Sensitivity 
Time 
Duration of 
Drug 
Exposure 
(Days) 
Sensitivity 
Puromycin 1-10 Not Tested Not Tested 5 Resistant 
G418 100-1200 4 
Sensitive 
O.C (1000 
µg/mL) 
17 o.m.p Resistant 
Hygromycin 100-1200 4 
Sensitive 
O.C (600 
µg/mL) 
7 o.m.p Resistant 
Blasticidin 10-50 Not Tested Not Tested 2 days 
Sensitive 
O.C (20 
µg/mL) 
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In summary, HaCaT-Ras cells were only sensitive to blasticidin, in contrast to HaCaT 
cells which were sensitive to both G418 and hygromycin.  
Transfection, sorting of transfected cells, and selection of clones. 
As an alternative approach to drug-selection, we decided to co-transfect HaCaT and 
HaCaT-Ras cells with PKC-δ promoter-reporter plasmid and an enhanced green 
fluorescent protein (EGFP) plasmid, and sort EGFP transfected cells by flow cytometry 
later on. Sorted EGFP+ cells should express PKC-δ promoter-reporter as the quantity of 
PKC-δ reporter plasmid used for transfection was much higher than quantity of GFP 
plasmid. Also we proposed that EGFP fluorescence in cells could serve as an internal 
control for cell viability. Figure 6 illustrates the complete approach of cell sorting to 
develop stable, pGL3-hPKCδ-4.4 transfected cell lines. 
We co-transfected pGL3-hPKCδ-4.4 plasmid in excess of pEGFP-C1 plasmid (4:1 ratio) 
in both HaCaT and HaCaT-Ras cells using FuGENE 6. 24 hours after transfection, we 
could visualize fluorescent HaCaT and HaCaT-Ras cells under fluorescent microscope, 
confirming that both the cells were transfected with pEGFP-C1. On the next day highly 
EGFP+ HaCaT and HaCaT-Ras cells were sorted by FACS (Figure 7). 17.5 percent of 
HaCaT-Ras cells were highly EGFP+ after primary bulk-sorting (Figure 7 B). The 
percentage of highly EGFP+ HaCaT-Ras cells here reflects transfection efficiency of 
pEGFP-C1 in HaCaT-Ras cells. Sorted cells were plated in 96 well plates at single cell 
per well. Also 20,000 and 50,000 bulk sorted HaCaT and HaCaT-Ras cells respectively, 
were plated in p35 plates. 48 hours after plating, we could visualize a single fluorescent 
cell in many but not all wells of 96 well plates (Figure 8). After 11 days, we again sorted 
highly EGFP+ cells from the HaCaT- Ras cells that were plated in p35 after first sorting. 
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2.4 percent of HaCaT-Ras cells were highly EGFP+ after secondary bulk-sorting (Figure 
7 C). The percentage of highly EGFP+ HaCaT-Ras cells here reflects percentage of 
HaCaT-Ras cells stably transfected with pEGFP-C1. Taking into account percentages of 
highly EGFP+ cells from both the figures 7A and 7C (17.5 and 2.4 respectively), it could 
be interpreted that out of 100% highly EGFP+ HaCaT-Ras cells sorted in primary sort, 
around 98% cells lost their EGFP expression by 10 days. Secondary sorted highly 
EGFP+ HaCaT-Ras cells were also plated in 96 well plates at single cell per well to select 
clones. 
We allowed sufficient time for clones to grow in 96 well plates, and selected clones 
which showed good growth rates. We selected 3 clones of HaCaT cells from sorted 
highly EGFP+ HaCaT cells. 7 and 4 clones of HaCaT-Ras were selected from highly 
EGFP+ HaCaT-Ras cells sorted for the first time and second time respectively. Selected 
clones were frozen down and stored in liquid nitrogen at -80˚ C. 
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Figure 6: Schematic of transfection and sorting of cells followed by selection of 
clones for screening: pGL3-hPKCδ-4.4 and pEGFP-C1 were co-transfected into 
HaCaT and HaCaT-Ras cells in ratio of 4:1 using FuGENE 6. Ratio of 4:1 was 
used for amounts of pGL3-hPKCδ-4.4 and pEGFP-C1 so that probability of 
EGFP+ cells being transfected with pGL3-hPKCδ-4.4 is high. Flow cytometric cell 
sortings for highly EGFP+ cells were performed two times, followed by plating 
one highly EGFP+ cell per well of 96 well plates each time. After indicated time 
periods HaCaT-Ras and HaCaT clones were collected and frozen down at -80˚ C.  
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97.6% 
2.4% 17.5
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82.5% 
4.5% 
95.5% 
(B) HaCaT-Ras- 
Primary sorting 
(C) HaCaT-Ras- 
Secondary 
sorting 
(A) HaCaT 
Figure 7: Flow cytometric sorting of highly EGFP+ HaCaT and HaCaT-Ras 
cells: In flow-cytometric analysis, percentages of highly pEGFP-C1+ cells were 
quantified in single cell population, gated from mixed cell population. 4.5% 
HaCaT cells (A) and 17.5% HaCaT-Ras cells (B) were found highly EGFP+ 48 
hours post-transfection. This was followed by sorting, plating and expansion of 
highly EGFP+ cells in bulk. After 11 days, primary sorted HaCaT-Ras cells were 
sorted again and 2.4% HaCaT-Ras cells (C) were highly EGFP+. 
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Screening of selected clones 
Approximately 60 days after freezing down the clones, all the frozen clones were thawed 
to screen for clones which were stably transfected. None of the HaCaT clones were 
EGFP+, however 4 out of 11 HaCaT-Ras clones were EGFP+ after thawing. The 4 
EGFP+ HaCaT-Ras clones were clones 8, 9, 10 and 11. 
Screening of HaCaT-Ras clones was performed in two batches (Figure 9 and 10), in 
which the HaCaT and HaCaT-Ras clones were plated in 96 well plates, and luciferase 
activity for each clone was measured in PHERAstar FS 72 hours after plating. Also, 24 
hours after plating clones were treated with 250 µM PP2 to see the inducibility of 
reporter activity in each clone. In screening, the only clone found stably transfected with 
pGL3-hPKCδ-4.4 was clone 9 (Figure 10 A). Difference between reporter activities of 
clone 9 and untransfected control was more than 100-fold and significant (Figure 10 B, 
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Figure 8: Single EGFP+ HaCaT-Ras cell in a 96 well plate: Image of a 
single EGFP+ HaCaT-Ras cell in 96 well plate observed 48 hours after 
plating. Objective: 4X 
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p<0.005). On the other hand, reporter activity of clone 9 was drastically less compared to 
transiently transfected HaCaT-Ras cells, a positive control for this experiment (Figure 10 
A). None of the HaCaT-Ras clones showed induction in PKC-δ reporter activity when 
treated with PP2 (Figure 9, 10). None of the HaCaT clones showed reporter activity 
higher than untransfected control in screening (Data not shown). 
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Figure 9: HaCaT-Ras Clone Screening Batch 1: HaCaT-Ras clones were plated 
in 96 well plates. 24 hours later clones were treated with 250 µM PP2, and 48 
hours following drug treatment, luminescence was measured in PHERAstar FS 
with untransfected HaCaT-Ras as negative control and transiently transfected 
HaCaT-Ras as positive control. n=9 for untransfected, transiently transfected 
HaCaT-Ras cells and untreated clones, n=3 for treated clones. n= number of 
replicates for any data point in one experiment. Error bars denote standard 
deviations. 
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Figure 10: HaCaT-Ras Clone Screening Batch 2: HaCaT-Ras clones were 
plated in 96 well plates. 24 hours later clones were treated with 250 µM PP2, and 
48 hours following drug treatment, luminescence was measured in PHERAstar FS. 
(A) Luciferase activity measured on all the clones with untransfected HaCaT-Ras 
as negative control and transiently transfected HaCaT-Ras as positive control (B) 
Re-plotting of luciferase data in (A) showing difference between luciferase 
activities of untransfected control and clone 9. Each data point is average of 6 
replicates in one experiment. Error bars denote standard deviation. 
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PP2 induces PKC-δ promoter activity in HaCaT-Ras cells 
Next, we wanted to identify positive control compounds which could highly induce PKC-
δ promoter activity in HaCaT-Ras cells to develop a robust high throughput assay having 
a high Z value. In order to do that, HaCaT-Ras cells were co-transfected with pGL3-
hPKCδ-4.4 and pRL-CMV plasmids (in 16:1 ratio), and treated with PP2, LY294002 or 
Dasatinib one day post transfection. We hypothesized that src-family kinase inhibitors 
PP2 and Dasatinib, and PI3K inhibitor LY294002 would have potential to inhibit 
elements of Ras signaling pathway described earlier (Figure 4). 48 hours following drug 
treatments, firefly and renilla luciferase activities were measured by dual luciferase assay. 
As shown in Figure 11, PP2 (10 µM) treatment showed 1.5-fold induction in PKC-δ 
promoter activity compared to untreated control. P value calculated for this difference of 
luciferase activities using Student’s T test, was less than 0.005. As 0.05 is a pre-
determined significance threshold, we considered this induction in reporter activity as 
statistically significant. LY294002 (10 µM) treatment led to significant decrease in PKC-
δ promoter activity, whereas Dasatinib (10 nM) treatment did not change it significantly 
(Figure 11).  
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Optimization of PHERAstar FS for fluorescence and luminescence measurements 
We sought to optimize PHERAstar FS for fluorescence and luminescence measurements 
in this project. We checked if PHERAstar FS had ability to detect fluorescent signals 
emitted by pEGFP-C1 transfected HaCaT-Ras cells in 96 well plates. As shown in Figure 
12, EGFP transfected HaCaT-Ras cells showed very high fluorescence intensity 
compared to untransfected HaCaT-Ras cells in PHERAstar FS. In contrast, there was no 
significant difference observed between fluorescence of EGFP transfected and 
untransfected HaCaT cells, indicating very low transfection efficiency (Figure 12). 
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Figure 11: Dual luciferase assay on HaCaT-Ras cells after different drug 
treatments: pGL3-hPKCδ-4.4 and pRL-CMV were co-transfected into HaCaT-
Ras cells in relative amounts of 16:1 using TransIT 2020. 24 hours after 
transfection, cells were treated with indicated concentrations of PP2, LY294002, 
and Dasatinib. Dual luciferase assay was performed 48 hours following drug 
treatments. Each data point shown in figure is average of three replicates in one 
experiment. Error bars denote standard deviation. 
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Figure 13 shows the luminescence measurements carried out on the PHERAstar FS on 
pGL3-hPKCδ-4.4 transfected HaCaT-Ras cells, with or without 10 µM PP2 treatment. It 
is noticeable that luminescence measured in pGL3-hPKCδ-4.4 transfected HaCaT-Ras 
cells was more than 10-fold higher compared to untransfected control (Figure 13). 
Further, luciferase activity was significantly increased when transfected cells were treated 
with PP2 (Figure 13). 
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Figure 12: Fluorescence measurement in PHERAstar FS: HaCaT and HaCaT-
Ras cells were transfected with indicated plasmids using FuGENE 6, and plated in 
a 96 well plate 24 hours after transfection. 48 hours after plating, fluorescence 
intensity was measured in PHERAstar FS. Note the high RFU value for EGFP 
transfected HaCaT-Ras cells. Here n = number of replicates for each data point in 
one experiment. Error bars denote standard deviations. 
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To decide the optimal time point of reading luminescence in PHERAstar FS after 
addition of Steady-Glo Luciferase assay reagent, we measured luminescence at different 
time points after addition of assay reagent in addition to following manufacturer’s 
recommended protocol of measuring luminescence 10 minutes after adding assay reagent 
(Figure 14). As seen in Figure 14, for both PP2 treated and untreated HaCaT-Ras cells 
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Figure 13: Luminescence measurement in PHERAstar FS: HaCaT and 
HaCaT-Ras cells were transfected with pGL3-hPKCδ-4.4 using FuGENE 6, and 
on next day, transfected cells were plated in a 96 well plate. 24 hours after plating, 
cells were treated with 10 µM PP2. Luminescence was measured in PHERAstar 
FS 48 hours following drug treatment. Note RLU values in transfected cells with 
or without PP2 treatment. n = 5 for all data points. Here n = number of replicates 
for each data point in one experiment. Error bars denote standard deviations. 
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luciferase activity was fairly similar over time. Although it increased to small extent after 
50 minutes, increases in PP2 treated and untreated cells were similar (Figure 14). As 
measuring luminescence after longer waiting times (50, 60 minutes) did not offer any 
advantages, we chose 10 minutes as an optimal time point for reading luminescence after 
adding reagent. 
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Figure 14: Luminescence measurement in PHERAstar FS over different time 
points: HaCaT-Ras cells were transfected with pGL3-PKC-δ-4.4 plasmid using 
FuGENE 6, and on next day transfected cells were plated in a 96 well plate. 24 
hours after plating, cells were treated with 10 µM PP2. 48 hours following drug 
treatment, luminescence was measured in PHERAstar FS 0, 10, 50 and 60 minutes 
after adding Steady-Glo Luciferase assay reagent. RLU values shown in the graph 
are averages of five replicates in one experiment. 
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We also carried out experiment to determine best optic settings in PHERAstar FS to 
measure signals from a 96 well plate, and obtained the following results for three 
important optic parameters of PHERAstar FS. 
1. Measurements by ‘Bottom Optics’ were more sensitive and accurate compared to 
those by ‘Top Optics’ (Data not shown).  
2. Using ‘Orbital Averaging’ during read-outs increased agreeability of readings 
amongst replicates of similar groups (Figure 15). However, orbital averaging did 
not affect magnitude of signals. 
3. We read fluorescence signals on PHERAstar FS using different numbers of 
flashes per well in the range of 0 to 159, and found that increasing number of 
flashes per well increased accuracy of read-outs (Data not shown). So we used 
159 flashes per well to measure fluorescence in PHERAstar FS. 
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Figure 15: Orbital averaging in PHERAstar FS improves precision of 
fluorescence measurements: HaCaT-Ras cells were transfected with pGL3-PKC-
δ-4.4 plasmid using FuGENE 6, and on next day transfected cells were plated in a 
96 well plate. 24 hours after plating, cells were treated with indicated drugs. 48 
hours following drug treatment, luminescence was measured in PHERAstar FS. 
%CV was calculated from fluorescence intensities of three replicates in one 
experiment. 
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Higher doses of PP2 lead to higher induction in PKC-δ reporter activity 
To characterize dose-response effect of PP2 on HaCaT-Ras cells, we treated pGL3-PKC-
δ-4.4 transfected HaCaT-Ras cells with increasing doses of PP2 and found that increase 
in dose of PP2 results in higher induction in PKC-δ promoter activity (Figure 16). 
Highest fold induction in reporter activity compared to control was 2.61-fold for 100 µM 
PP2 (Figure 16). Moreover, there was no peak effect observed in the dose-response curve 
(Figure 16, note last two columns). 
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Combination of Bay 11-7085 and TPA induces PKC-δ reporter activity 
In experiments similar to the one described earlier (Figure 16), we tested different 
compounds and combination of compounds for their ability to induce PKC-δ reporter 
activity (Figure 17, 18). The compounds tested included proteosome inhibitor 
Bortezomib (61), NF-κB inhibitor Bay 11-7085, PI3K inhibitor GDC-0941 which were 
used to inhibit elements of proposed Ras signaling pathway earlier (Figure 4) and TNF-α, 
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PKCδ promoter activity for HaCaT-Ras cells 48h after 
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Figure 16: PP2 Dose-Response Relationship: HaCaT-Ras cells were transfected 
with pGL3-PKC-δ-4.4 using FuGENE 6, and plated in 96 well plate on the next 
day. 24 hours after plating, cells were treated with different concentrations of PP2. 
48 hours following drug treatment, luciferase activity was measured in 
PHERAstar FS.  n= 4 for PP2 (1 µM), n=6 for other data points, where n= number 
of replicates for data point in one experiment. FI = Fold Induction. Error bars 
denote standard deviations. 
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Vitamin D3, Estrogen, Insulin and TPA which were shown to induce PKC-δ gene 
expression in other studies (24, 62-65). As evident in Figure 18, combination of 25 µM 
Bay 11-7085 and 50 nM TPA gave the highest induction in reporter activity amongst all 
compounds or combination of compounds tested. 
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Figure 17: Testing different compounds for their ability to induce PKC-δ 
promoter activity 1: HaCaT-Ras cells were transfected with pGL3-PKC-δ-4.4 
using FuGENE 6, and plated in 96 well plate on the next day. 24 hours after 
plating, cells were treated with indicated concentrations of Bortezomib, Vitamin 
D3, TNF-α, Estrogen, and Insulin. 48 hours following drug treatment, luciferase 
activity was measured in PHERAstar FS.  n= 9 for untreated, n=3 for other data 
points, where n= number of replicates for data point in one experiment. Dotted 
line indicates basal PKC-δ reporter activity in untreated HaCaT-Ras cells on 
graph. Error bars denote standard deviations. 
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Figure 18: Testing different compounds for their ability to induce PKC-δ 
promoter activity 2: HaCaT-Ras cells were transfected with pGL3-PKC-δ-4.4 
using FuGENE 6, and plated in 96 well plate on the next day. 24 hours after 
plating, cells were treated with indicated concentrations of Bay 11-7085, Bay 11-
7085+TPA, GDC-0941, GDC-0941+TPA and TPA. 48 hours following drug 
treatment, luciferase activity was measured in PHERAstar FS.  n= 9 for untreated, 
n=3 for other data points, where n= number of replicates for data point in one 
experiment. Dotted line indicates basal PKC-δ reporter activity in untreated 
HaCaT-Ras cells on graph. Error bars denote standard deviations. 
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Z value calculations 
Z values for the two candidate assays in which positive control compounds showed 
highest induction in PKC-δ reporter activity, were calculated by equation described 
earlier (59). The first assay, consisting of combination of Bay 11-7085 and TPA as a 
positive control (Figure 18, column 1 as a negative control, column 4 positive control), 
gave Z value of -0.06 after analysis. Following interpretations for Z values described in 
section 1.7 in background, this assay was unacceptable for high throughput screening. 
Second assay, which employed PP2 as a positive control (Figure 16, column 1 as a 
negative control, column 6 positive control), gave Z value of 0.19. Z value of 0.19 could 
be interpreted as a doable assay (Table 1). However, none of the candidate assays had our 
desired Z value of 0.5 or above to generate an excellent assay. So in order to obtain 
higher Z values, we attempted to find ways to increase the induction in reporter activity 
with drug treatments and decrease the variability of luminescence.  
Treatment of HaCaT-Ras cells with PP2 reduces number of attached cells 
If drug treatments had any effect on number or viability of HaCaT-Ras cells, those effects 
would also have effects on the luciferase activities of treated cells. Therefore it was 
important to know whether or not drugs being used in this project had any effects on 
number or viability of HaCaT-Ras cells, and if they did, to find out a convenient way to 
normalize the luminescence data with cell number or viability. When EGFP transfected 
HaCaT-Ras cells were treated with 10 µM PP2 for 48 hours, they showed formation of 
clusters and reduction in number of attached cells (Figure 19).  
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Bright Field Fluorescent 
HaCaT-Ras 
HaCaT-Ras 
+ 
PP2 (10 µM) 
 
Figure 19: Effect of PP2 on morphology and number of attached HaCaT-Ras 
cells: HaCaT-Ras cells were transfected with EGFP using FuGENE 6, and plated 
in 96 well plate on the next day. 24 hours after plating, cells were treated with 10 
µM PP2.  Images shown here were captured in fluorescent microscope 48 hours 
after PP2 treatment. Objective: 4X 
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EGFP fluorescence does not reflect number of attached HaCaT-Ras cells observed 
on plate 
When we treated EGFP transfected HaCaT-Ras cells with drugs PP2, Bortezomib and 
MG132 (another proteasome inhibitor), we found poor correlation between number of 
attached HaCaT-Ras cells observed under microscope and fluorescence measured in 
PHERAstar FS after drug treatments (Figure 20). Specifically, with 1 µM PP2 treatment, 
reduction in number of attached cells observed under microscope (Figure 20 B, second 
column) was not reflected in fluorescence measurement as a reduction in fluorescence 
intensity (Figure 20 A, third bar). This was also true for 1 µM MG132 treatment (Figure 
20 A-fourth lane, B -third image). Thus EGFP fluorescence was not a reliable method to 
normalize for cell number and viability. 
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Figure 20: Poor correlation between fluorescence read by PHERAstar FS and 
number of attached cells observed for HaCaT-Ras cells treated with different drugs: 
Treatments with the indicated drugs were started on HaCaT-Ras cells, co-transfected with 
pGL3-hPKC-δ-4.4 kb and EGFP 24 hours post-transfection. Then (A) Fluorescence was 
measured using PHERAstar FS, 48 hours post drug treatments. Error bars denote standard 
deviations (B) Cells were observed under fluorescent microscope, 24 hours after initiation 
of drug treatments. Shown are the images of PP2 (1 µM), MG132 (1 µM), and 
Bortezomib (200 nM) treated cells. Objective: 4X. n=6 for Untreated, n=3 for all drug 
treatments, n= number of replicates for any data point in one experiment. 
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Viability of HaCaT-Ras cells decreases after PP2 treatment 
We used different methods of measuring cell viability to see if reduction in number of 
attached cells observed after PP2 treatment (Figure 20 B) is actually reduction in cell 
viability or not. Indeed, PP2 treatment decreased number of viable HaCaT-Ras cells as 
measured by Alamar Blue and Cell-Titer Fluor Cell Viability Assays (Figures 21,22). 
Reduction in cell viability assay was 16% using Alamar Blue after 200 µM PP2 treatment 
(Figure 21), whereas it was 57% using Cell-Titler Fluor Cell Viability assay after 250 µM 
PP2 treatment (Figure 22). 
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Figure 21: Cell viability measurements using Alamar Blue Assay: pGL3-
hPKC-δ-4.4 kb transfected HaCaT-Ras cells were plated in 96 well plate. 24 hours 
after plating, cells were treated with PP2. 48 hours after drug treatments, cell 
viability was measured using Alamar Blue assay following manufacturer’s 
protocol. n=6 for all data points, where n = number of replicates for any data point 
in one experiment. Error bars denote standard deviations. 
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Figure 22: Cell viability measurements using Cell-Titler Fluor Viability 
Assay: HaCaT-Ras cells were plated in 96 well plate. 24 hours after plating, cells 
were treated with PP2. 48 hours after drug treatments, cell viability was measured 
using Cell-Titler Fluor Viability assay following manufacturer’s protocol. n 2 for 
all data points, where n = number of replicates for any data point in one 
experiment. Error bars denote range. 
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Effect of shaking on variability of luminescence 
To reduce variability in luminescence read-outs in PHERAstar FS, we employed a 
shaking step in our protocol and assessed how it affects %CV (Co-efficient of Variation) 
of luminescence read-outs. We saw reduction in %CV after shaking the plate for up to 10 
minutes after measuring luminescence by Steady-Glo Luciferase Assay protocol (reading 
luminescence 10 minutes after addition of assay reagent without shaking the plate) 
(Figure 23 A). Shaking for more than 10 minutes after first measurement resulted in 
increase in %CV (Figure 23 A, time point 4 and 5). Figure 23 B depicts the luminescence 
values read on PHERAstar FS in this experiment. 
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(A) Effect of shaking on variability in luminescence in HaCaT-
Ras cells treated with Bay11+TPA 
Figure 23 (A): Shaking reduces variability of luminescence read-outs in 
PHERAstar FS: pGL3-hPKC-δ-4.4 kb transfected HaCaT-Ras cells were plated 
in 96 well plate. 24 hours after plating, cells were treated with combination of 25 
µM Bay 11-7085 and 50 nM TPA. 48 hours after drug treatments, luminescence 
was measured in PHERAstar FS at different time points described in figures. 
Briefly, for first time point, company protocol was followed to measure luciferase 
activity without shaking and each of subsequent measurements included 5 minutes 
shaking period. (A) shows %CV calculated from (B) luminescence values for all 
groups (See next page). For each time point cumulative shaking time in mentioned 
in figure. Speed and motion of shaking of most recent shaking is mentioned in 
brackets. 
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Figure 23 (B): Shaking reduces variability of luminescence read-outs in 
PHERAstar FS: pGL3-hPKC-δ-4.4 kb transfected HaCaT-Ras cells were plated 
in 96 well plate. 24 hours after plating, cells were treated with combination of 25 
µM Bay 11-7085 and 50 nM TPA. 48 hours after drug treatments, luminescence 
was measured in PHERAstar FS at different time points described in figures. 
Briefly, for first time point, company protocol was followed to measure luciferase 
activity without shaking and each of subsequent measurements included 5 minutes 
shaking period. (B) shows luminescence values for all groups. n= 6 for all data 
points, where n = number of replicates for any data point in one experiment. For 
each time point cumulative shaking time in mentioned in figure. Speed and motion 
of shaking of most recent shaking is mentioned in brackets. Error bars denote 
standard deviations. 
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We also looked at the effect of shaking on variability of luminescence in HaCaT-Ras 
cells treated with PP2. We found that increase in shaking time results in decrease in %CV 
of luminescence (Figure 24 A). Again, we noticed that at time point 3 (after 10 minutes 
of shaking) %CV was low for both untreated and PP2 treated HaCaT-Ras cells, but 
increasing shaking time beyond that resulted in increase in %CV for PP2 treated cells 
(Figure 24 A). 
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Figure 24 (A): Effect of shaking on PP2 treated HaCaT-Ras cells: pGL3-
hPKC-δ-4.4 kb transfected HaCaT-Ras cells were plated in 96 well plate. 24 hours 
after plating, cells were treated with 250 µM PP2. 48 hours after drug treatments, 
luminescence was measured in PHERAstar FS at different time points indicated in 
figures. Briefly, for first time point, company protocol was followed to measure 
luciferase activity without shaking and each of subsequent measurements included 
5 minutes shaking period. (A) shows %CV calculated from (B) luminescence 
values for all groups (See next page). For each time point cumulative shaking time 
in mentioned in figure. Speed and motion of shaking of most recent shaking is 
mentioned in brackets. 
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(B) Effect of shaking on luminescence measurements in 
HaCaT-Ras cells after PP2 treatment 
Figure 24 (B): Effect of shaking on PP2 treated HaCaT-Ras cells: pGL3-
hPKC-δ-4.4 kb transfected HaCaT-Ras cells were plated in 96 well plate. 24 hours 
after plating, cells were treated with 250 µM PP2. 48 hours after drug treatments, 
luminescence was measured in PHERAstar FS at different time points indicated in 
figures. Briefly, for first time point, company protocol was followed to measure 
luciferase activity without shaking and each of subsequent measurements included 
5 minutes shaking period. (B) shows luminescence values for all groups. n= 6 for 
all data points, where n = number of replicates for any data point in one 
experiment. For each time point cumulative shaking time in mentioned in figure. 
Speed and motion of shaking of most recent shaking is mentioned in brackets. 
Error bars denote standard deviations. 
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To see if adding shaking step right after addition of reagent reduces variability or not, we 
performed experiment similar to figure 23 except with shaking the plate right after adding 
the reagent this time. Interestingly, %CVs after shaking the plate right after addition of 
reagent were higher than ones where plate was not shaken ( 8.6 and 10.6 for untreated 
cells at time points 1 in Figure 23 A and 25 A respectively, and 7.2 and 8 for treated cells 
at time points 1 in Figure 23 A and 25 A respectively). Secondly, shaking the plate at first 
time point did not lead to reduction in %CV in at least two subsequent time points as 
much as seen without shaking plate at first time point (First three time points in untreated 
cells in 23 A are 8,6.1 and 4.5, whereas in 25 A are 10.5, 9.6 and 8.7). Therefore, we 
found that the optimal shaking duration to achieve lowest %CVs was 10 minutes, where 
shaking of the plates was started 10 minutes after addition of the reagent. 
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Figure 25 (A): Shaking plate right after addition of luciferase reagent is not 
beneficial to reduce variability: pGL3-hPKC-δ-4.4 kb transfected HaCaT-Ras 
cells were plated in 96 well plate. 24 hours after plating, cells were treated with 
combination of 25 µM Bay 11-7085 and 50 nM TPA. 48 hours after drug 
treatments, luminescence was measured in PHERAstar FS at different time points 
described in figures. Briefly, for first time point, plate was shaken for 5 minutes 
right after addition of reagent and luminescence was measured 10 minutes after 
shaking. Each of subsequent measurements included additional 5 minutes shaking 
period. (A) shows %CV calculated from (B) luminescence values for all groups 
(See next page). For each time point cumulative shaking time in mentioned in 
figure. Speed and motion of shaking of most recent shaking is mentioned in 
brackets. 
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Figure 25 (B): Shaking plate right after addition of luciferase reagent is not 
beneficial to reduce variability: pGL3-hPKC-δ-4.4 kb transfected HaCaT-Ras 
cells were plated in 96 well plate. 24 hours after plating, cells were treated with 
combination of 25 µM Bay 11-7085 and 50 nM TPA. 48 hours after drug 
treatments, luminescence was measured in PHERAstar FS at different time points 
described in figures. Briefly, for first time point, plate was shaken for 5 minutes 
right after addition of reagent and luminescence was measured 10 minutes after 
shaking. Each of subsequent measurements included additional 5 minutes shaking 
period. (B) shows luminescence values for all groups. n= 6 for all data points, 
where n = number of replicates for any data point in one experiment. For each 
time point cumulative shaking time in mentioned in figure. Speed and motion of 
shaking of most recent shaking is mentioned in brackets. Error bars denote 
standard deviations. 
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PKC-δ mRNA levels in HaCaT-Ras cells 
We were concerned if our HaCaT-Ras cells still had repressed PKC-δ gene expression 
because (i) we always observed high basal PKC-δ reporter activity in transiently 
transfected HaCaT-Ras cells (Figure 9, 10 A), and (ii) PKC-δ reporter activity could not 
be highly induced in these cells even at higher concentrations of PP2 (Figure 16). To 
answer this question, we measured steady state mRNA levels of PKC-δ in HaCaT-Ras 
cells by qRT-PCR and found that they were not lower compared to those in the HaCaT 
cells (Figure 26), as had been reported previously (17,23). Instead, PKC-δ mRNA levels 
were three fold higher in HaCaT-Ras cells than those in HaCaT cells (Figure 26). 
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Figure 26: PKC-δ mRNA levels are not reduced in HaCaT-Ras cell line: RNA 
from both the HaCaT and HaCaT-Ras cells were isolated, and qRT-PCR was 
performed to check mRNA levels of PKC-δ after conversion of RNA to cDNA. 
n=3 for all data points, where n = number of replicates for any data point in one 
experiment. Error bars denote standard deviations. 
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Ras mRNA levels in HaCaT-Ras cells 
Since Ras is an upstream mediator of our proposed signaling pathway leading to PKC-δ 
gene repression in HaCaT-Ras cells (25), we measured mRNA levels of Ras  in HaCaT-
Ras cell lines to see if they still over-express Ras protein compared to HaCaT cells. 
Steady state mRNA levels of Ras were not up regulated in two different thaws of HaCaT-
Ras cells of our laboratory compared to HaCaT cells (Figure 27), as determined by qRT-
PCR.  
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Figure 27: Ras mRNA levels are reduced in HaCaT-Ras cell line: RNAs from 
HaCaT and two different thaws of HaCaT-Ras cells, HaCaT-Ras KP and HaCaT-
Ras SF were isolated, and qRT-PCR was performed to check mRNA levels of Ras 
after conversion of RNA to cDNA. n=3 for all data points, where n = number of 
replicates for any data point in one experiment. Error bars denote standard 
deviations. H.Ras KP = HaCaT-Ras cells cultured by Kushal Prajapati, and H.Ras 
SF = HaCaT-Ras cells cultured by Sarah Fenton. Both the H.Ras KP and H.Ras 
SF belonged to the same frozen stock of HaCaT-Ras cells. 
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PKC-δ mRNA levels in HaCaT-Fyn cells 
Since HaCaT-Ras cells no longer had lower endogenous PKC-δ levels (Figure 26) and 
higher endogenous Ras levels, we sought to find out another cell line having reduced 
PKC-δ levels that could be used to continue this study. We assessed endogenous PKC-δ 
mRNA levels of Fyn transformed HaCaT cells, HaCaT-Fyn as high Fyn activity may lead 
to reduction in PKC-δ gene expression (Figure 4). We also checked PKC-δ mRNA levels 
of triple negative breast cancer cells, MDA-MB-231 with or without 10 µM LY294002 
treatment to see if they have PI3K mediated repression of PKC-δ transcription. Using 
qRT-PCR, we found that HaCaT-Fyn cells had higher PKC-δ mRNA levels compared to 
HaCaT cells (Figure 28). When MDA-MB-231 cells were treated with 10 µM 
LY294002, they showed higher PKC-δ mRNA levels compared to untreated control 
(Figure 28). However, this data could not be recapitulated in a dual luciferase assay, 
wherein we found decrease in PKC-δ mRNA levels in MDA-MB-231 cells after 
LY294002 treatment (Figure 29). 
  
59 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.000 
0.500 
1.000 
1.500 
2.000 
2.500 
3.000 
3.500 
4.000 
4.500 
HaCaT HaCaT Fyn MDA MB 231 MDA MB 231 + 
LY294002 
R
el
a
ti
v
e 
P
K
C
-δ
 m
R
N
A
 l
ev
el
s 
n
o
rm
a
li
ze
d
 t
o
 
G
A
P
D
H
 
Cells  
Endogenous PKC-δ mRNA levels measured by RT-PCR 
Figure 28: PKC-δ mRNA levels in HaCaT-Fyn and MDA-MB-231: HaCaT-
Fyn, MDA-MB-231 cells were plated in a way that they were around 60% 
confluent the next day. On next day, treatment with 10 µM LY294002 was started 
on MDA-MB-231. 24 hours after that RNA from all cells were isolated, and qRT-
PCR was performed to check mRNA levels of PKC-δ. n 3 for all data points, 
where n = number of replicates for any data point in one experiment. Error bars 
denote standard deviations. 
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Figure 29: Dual luciferase assay on MDA-MB-231 cells after different drug 
treatments: pGL3-hPKCδ-4.4 and pRL-CMV were co-transfected into MDA-
MB-231 cells in relative amounts of 9:1 using Lipofactamine. 24 hours after 
transfection, cells were treated with indicated concentrations of PP2 and 
LY294002. Dual luciferase assay was performed 24 hours following drug 
treatments. Each data point shown in figure is average of three replicates. Error 
bars denote standard deviation. 
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CHAPTER 4  
DISCUSSION 
The goal of this study was to develop a stable, high-throughput screening PKC-δ reporter 
assay that allows screening of high number of compounds having a potential to induce 
PKC-δ gene expression in both academic and industrial settings. To develop a stably 
transfected cell line, drug selection approach is a commonly utilized by scientists (57, 
58). In our case, HaCaT-Ras cells were resistant to most of the selection drugs but the 
blasticidin. We did not have any mammalian-expression vector carrying blasticidin 
resistance gene to select the transfected cells using blasticidin. Although we could sub-
clone a blasticidin resistance gene in mammalian-expression vector, we proposed an 
alternative approach of developing a stably transfected cell line to save time. We 
proposed an approach which involved co-transfection with PKC-δ reporter plasmid and 
EGFP, followed by flow-cytometric sorting of EGFP+ cells to select stably transfected 
cells. Although the drawback of this approach is that cells are not always under selection 
pressure to allow elimination of cells which lose plasmids over time, the advantage is that 
cells stably transfected with EGFP could be easily determined by observing fluorescent 
cells under microscope. Hereby, we utilized this approach and were successful in 
generating a HaCaT-Ras cell line stably expressing the pGL3-hPKCδ-4.4 reporter 
plasmid.
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For selecting the most appropriate clone for assay development, growth, stable 
transfection and inducibility of reporter activity after treatment with positive control 
compound PP2 were major criterions. Although we obtained a clone stably transfected 
with pGL3-hPKCδ-4.4kb plasmid (Clone 9), inducibility of reporter activity after PP2 
treatment was absent in all the clones. The reason for lack of inducibility in reporter in 
clones may be attributed to the fact that at some point of time HaCaT-Ras cells stopped 
activating our proposed Ras pathway (Figure 4, 26, 27) leading to PKC-δ promoter 
repression.  
Searching a good positive control compound which robustly induces PKC-δ promoter 
activity was a challenging task as gene regulation of PKC-δ has not been studied 
extensively in the past, and so not many compounds increasing PKC-δ gene expression 
are known. To find out a positive control that highly induces our 4.4 kb-PKC-δ promoter 
activity, we chose specific compounds which would inhibit components of proposed Ras 
signaling pathway (Figure 4), and compounds which increased PKC-δ gene expression in 
other studies. We found the src family kinase inhibitor PP2 to be the best inducer of 
PKC-δ promoter activity in HaCaT-Ras cells (Figure 16). The results of NF-κB inhibitor-
Bay 11-7085 alone leading to reduction in PKC-δ promoter activity (Figure 18, column 2, 
3) suggested that NF-κB might be a positive regulator of PKC-δ transcription. This was 
in congruence with earlier human PKC-δ promoter studies reported on mouse fibroblasts 
by Liu et al. (25). Interestingly, combination of Bay 11-7085 and PKC activator-TPA 
induced PKC-δ promoter activity, as a result of synergy between the two compounds. On 
the other hand, TNF-α, vitamin D3, estrogen, and insulin did not induce PKC-δ reporter 
activity. These findings were not consistent with previous reports (24, 63-65), possibly 
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because the cell systems used in those studies were different than our cell model system. 
Substantial efforts were put to optimize the high-throughput assay protocol in 
PHERAstar FS. For all the single luciferase assays carried out in PHERAstar FS using 
Steady-Glo Luciferase Assay System, it should be noted that there was no internal control 
(such as Renilla luciferase) to normalize the data for transfection efficiency like in dual 
luciferase assays, and it was assumed that transfection efficiencies of pGL3-hPKCδ-4.4 
for all the HaCaT-Ras cells plated in multiple wells were similar. Also in these 
experiments Steady-Glo Luciferase Assay System was injected into wells using 
automatic injectors of PHERAstar FS against Promega’s protocol recommendation of not 
using automatic injectors for this reagent to avoid frothing. We used relatively low 
automatic injection speed in PHERAstar FS, and found no visual evidence of frothing in 
media on the plate after automatic injection.  
The Z value was our yardstick to assess the usability of high-throughput assay developed 
in this project. We were able to develop an acceptable assay (Z=0.19) using PP2 as a 
positive control in this study, however were not successful in generating excellent assay 
having Z value 0.5 or higher. To improve quality of the assay, we aimed to increase the 
fold induction in PKC-δ promoter activity after drug treatment and reduce variability 
(%CV) of luminescence. As PP2 treatment caused reduction in number attached HaCaT-
Ras cells when observed under the microscope, we thought that it was important to 
normalize luciferase activity with cell number or viability to correct for the effect of 
reduced cell viability on induction in reporter activity for any compound in statistical 
analysis. Initially in this study we proposed to use EGFP fluorescence as an internal 
control for cell viability, however we could not do so as EGFP fluorescence did not 
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correlate with the number of attached cells observed under microscope (Figure 20). The 
probable reason for this phenomenon was that drug compounds had an effect on the 
transcription of EGFP through interaction with CMV promoter of pEGFP-C1 plasmid 
transfected into HaCaT-Ras cells. Using Alamar Blue and Cell Titer Fluor Viability 
assays, we showed that treating HaCaT-Ras cells with compounds such as PP2 reduces 
their viability (Figures 21, 22). However, both Alamar Blue and Cell Titer Fluor Viability 
assays interfered with luminescence measurements (Data not shown). Thus multiplexing 
any suitable cell viability measurement kit in a high throughput luciferase assay in a way 
that it does not affect luciferase measurements, and health of cells is an important 
challenge that needs to be addressed in future. In an attempt to reduce variability in 
luminescence measurements, we started shaking 96 well plates before reading 
luminescence on PHERAstar FS. As reported in an earlier study (66), shaking the plates 
before reading luminescence resulted in reduction in %CV in luminescence. We found 
that the optimal time point and duration of shaking to achieve lowest %CV values in our 
protocol were 10 minutes after adding the assay reagent and 10 minutes respectively 
(Figure 23 A).  
At some point of time during this study, our HaCaT-Ras cells lost active Ras pathway we 
proposed earlier and consequentially stopped expressing lower PKC-δ and higher Ras 
mRNA levels. It was difficult for us to explain the reason for this occurrence, however 
one possible reason we postulated was that HaCaT-Ras cells methylated and silenced 
retroviral-LTR promoter, which drove stable active Ras expression in these cells. As this 
signaling pathway was pivotal for this study, we could not continue to optimize the assay 
further until and unless we had a cell system expressing low PKC-δ promoter activity and 
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gene expression as a result of active Ras pathway (Figure 4). We hypothesized that Fyn 
transformed HaCaT cells, HaCaT-Fyn, have lower PKC-δ mRNA levels compared to 
those in HaCaT cells as Fyn plays role in proposed Ras pathway downstream of active 
Ras (Figure 4). However, experimental results we obtained were opposite to our 
hypothesis, as PKC-δ mRNA levels were higher in HaCaT-Fyn cells compared to HaCaT 
cells (Figure 28). Triple negative breast cancer cells MDA-MB-231 harbor endogenous 
KRAS mutation and were earlier shown to express lower Fyn mRNA levels when treated 
with LY294002 (67), suggesting PI3K mediated activation of Fyn in these cells. So we 
premised that MDA-MB-231 cells have active Ras pathway we proposed (Figure 4), and 
should have higher PKC-δ promoter activity and gene expression when treated with 
LY294002. Indeed, we detected higher PKC-δ mRNA levels (Figure 28), but not PKC-δ 
reporter activity (Figure 29) in MDA-MB-231 cells after LY294002 treatment. The 
probable reason for this contradictory data is that PKC-δ mRNA levels and promoter 
activity are not regulated in a similar manner in MDA-MB-231 cells. As a result, we 
were unsuccessful in finding out any other cell line that could substitute for HaCaT-Ras 
cells in this study.  
In summary, we successfully generated a HaCaT-Ras cell line stably transfected with 
pGL3-hPKCδ-4.4. We identified PP2 and combination of Bay 11-7085 and TPA as 
positive control compounds for developing high throughput PKC-δ promoter-reporter 
assay system. We also demonstrated importance of measuring cell viability and proposed 
Cell Titer Fluor Viability Assay as an assay system of preference to measure cell 
viability. A detailed protocol for this high throughput assay with specific focus on 
increasing Z value and convenience of operation in PHERAstar FS was developed in this 
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project. In future, stable cell system having active Ras pathway (Figure 4) and low PKC-
δ gene expression should be found out to verify findings of this study and continue 
improving the assay to obtain higher Z values. Human SCC cell line with endogenous 
HRAS mutation and low PKC-δ gene expression would be a reasonable substitute cell 
model. As an alternative approach, if active Ras pathway (Figure 4) could be transiently 
induced into HaCaT cells by transfection or viral infection of active Ras, a transient cell-
based assay to measure PKC-δ promoter activity could be developed. The tentative 
design of this transient assay in HaCaT cells comprises transient transfection or infection 
of active Ras, followed by transient transfection of luciferase reporter plasmids pGL3-
hPKCδ-4.4 and pRL-CMV (Renilla internal control), and measurement of luciferase 
activities at the last stage. Another possible approach is to induce over-activation of Ras 
in the HaCaT cells by treating them with EGF (22) and utilize them as a substitute for 
HaCaT-Ras cells. 
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